Shares in Subiaco-based biotech firm Phylogica have plummeted on the ASX after a potential licensing deal with a subsidiary of pharmaceutical giant Johnson & Johnson effectively collapsed.
Australian peptide drug discovery company Phylogica has announced a collaboration and option agreement with pharmaceutical giant Johnson & Johnson subsidiary Janssen Biotech Inc, to discover new
09 Jan 2012
Subscribe today for award-winning, unbiased and trusted journalism
